Q-omics provides the consensus-scored NRDE2 profile across patient tissues and cancer cell-line models. NRDE2 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, NRDE2 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, NRDE2 RNA expression shows 21,339 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight BRCA, HNSC, and ACC as cancer lineages where NRDE2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NRDE2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NRDE2 survival associations across molecular data types. NRDE2 RNA expression shows survival associations in the most cancer types (18), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NRDE2 RNA expression–survival associations across cancer types. High NRDE2 expression shows unfavorable associations in STAD, but favorable associations in BRCA, KIRC, ACC, GBM and THYM. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for NRDE2 RNA expression.
This table summarizes NRDE2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for NRDE2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NRDE2 shows lower tumor expression in THCA, KIRC and KICH and higher tumor expression in HNSC, LIHC and STAD. The HNSC box plot shows higher NRDE2 RNA expression in tumor versus normal tissue (log2 FC = +0.686, t-test p < 0.001).
This table shows molecular features associated with NRDE2 in patient tissues and cancer cell lines. In patient samples, NRDE2 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, NRDE2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
